Sanofi-Aventis U.S. LLC Sustainability Profile
Sanofi-Aventis U.S. LLC, a prominent subsidiary of the global healthcare leader Sanofi, is headquartered in the United States, with significant operations across North America. Founded in 2004, the company has established itself within the pharmaceutical industry, focusing on innovative solutions in areas such as diabetes, cardiovascular health, and rare diseases. Sanofi-Aventis is renowned for its diverse portfolio of core products, including insulin therapies and vaccines, which are distinguished by their commitment to patient-centric care and advanced research. The company has achieved notable milestones, including advancements in biologics and a strong market position as a trusted provider of essential medications. With a dedication to improving health outcomes, Sanofi-Aventis continues to play a vital role in the evolving landscape of global healthcare.
DitchCarbon Score
How does Sanofi-Aventis U.S. LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sanofi-Aventis U.S. LLC's score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sanofi-Aventis U.S. LLC, headquartered in the US, currently does not have specific carbon emissions data available for the most recent year, as indicated by the absence of emissions figures. The company is a current subsidiary of Sanofi, which cascades its climate commitments and emissions data from the parent organisation. Sanofi has set various climate initiatives, including targets under the Science Based Targets initiative (SBTi), and participates in the Carbon Disclosure Project (CDP) and RE100, which focuses on renewable energy commitments. However, specific reduction targets or achievements for Sanofi-Aventis U.S. LLC are not detailed in the available information. As a part of the broader Sanofi corporate family, the climate commitments and performance metrics are inherited from the parent company, Sanofi. This relationship underscores the importance of collective action within the pharmaceutical industry to address climate change and reduce carbon footprints.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2010 | 2011 | 2012 | 2013 | 2015 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 545,114,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 677,549,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 0,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Sanofi-Aventis U.S. LLC's Industry?
How Carbon Intensive is Sanofi-Aventis U.S. LLC's Location?
Sanofi-Aventis U.S. LLC's Scope 3 Categories Breakdown
Sanofi-Aventis U.S. LLC's Scope 3 emissions, which decreased by 5% last year and increased by approximately 40% since 2013, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 69% of Scope 3 emissions.
Top Scope 3 Categories
Sanofi-Aventis U.S. LLC's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Sanofi-Aventis U.S. LLC has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
